Overview
MicroRNA-155 (miR-155) is a multifunctional non-coding RNA that plays a critical role in immune regulation, inflammatory responses, and neurodegeneration. When packaged within extracellular vesicles (exosomes), miR-155 can traverse the blood-brain barrier and influence neuronal and glial cell function, making it both a promising biomarker and therapeutic target for neurodegenerative diseases including Alzheimer's Disease (AD), Parkinson's Disease (PD), and Multiple Sclerosis (MS). [@pmid]
miR-155 Dysregulation in Neurodegenerative Diseases
Alzheimer's Disease
In Alzheimer's Disease, miR-155 is significantly upregulated in brain tissue, cerebrospinal fluid (CSF), and peripheral blood. This dysregulation contributes to: [@microrna]
- Neuroinflammation: miR-155 promotes pro-inflammatory cytokine production in microglia
- Amyloid processing: Alters amyloid precursor protein (APP) metabolism
- Tau pathology: Modulates tau phosphorylation pathways
- Synaptic dysfunction: Impairs synaptic plasticity and memory formation
The elevation of exosomal miR-155 in CSF and blood of AD patients makes it a potential diagnostic biomarker. [@exosomemediated]
Parkinson's Disease
In Parkinson's Disease, miR-155 expression is altered in: [@mir]
- Dopaminergic neurons: Affected neurons show miR-155 upregulation
- Microglia: Promotes neuroinflammation via NF-κB pathway
- Peripheral blood: Exosomal miR-155 distinguishes PD from healthy controls
Multiple Sclerosis
...Overview
MicroRNA-155 (miR-155) is a multifunctional non-coding RNA that plays a critical role in immune regulation, inflammatory responses, and neurodegeneration. When packaged within extracellular vesicles (exosomes), miR-155 can traverse the blood-brain barrier and influence neuronal and glial cell function, making it both a promising biomarker and therapeutic target for neurodegenerative diseases including Alzheimer's Disease (AD), Parkinson's Disease (PD), and Multiple Sclerosis (MS). [@pmid]
miR-155 Dysregulation in Neurodegenerative Diseases
Alzheimer's Disease
In Alzheimer's Disease, miR-155 is significantly upregulated in brain tissue, cerebrospinal fluid (CSF), and peripheral blood. This dysregulation contributes to: [@microrna]
- Neuroinflammation: miR-155 promotes pro-inflammatory cytokine production in microglia
- Amyloid processing: Alters amyloid precursor protein (APP) metabolism
- Tau pathology: Modulates tau phosphorylation pathways
- Synaptic dysfunction: Impairs synaptic plasticity and memory formation
The elevation of exosomal miR-155 in CSF and blood of AD patients makes it a potential diagnostic biomarker. [@exosomemediated]
Parkinson's Disease
In Parkinson's Disease, miR-155 expression is altered in: [@mir]
- Dopaminergic neurons: Affected neurons show miR-155 upregulation
- Microglia: Promotes neuroinflammation via NF-κB pathway
- Peripheral blood: Exosomal miR-155 distinguishes PD from healthy controls
Multiple Sclerosis
miR-155 is particularly implicated in MS pathogenesis: [@bloodbrain]
- Autoimmune demyelination: miR-155 regulates T-cell differentiation
- Blood-brain barrier disruption: Increases endothelial permeability
- Microglial activation: Perpetuates inflammatory lesions
Exosomal Delivery Across the Blood-Brain Barrier
Exosomes provide a natural mechanism for miR-155 to cross the blood-brain barrier (BBB): [@microglial]
Mermaid diagram (expand to render)
Mechanisms of BBB Transcytosis
Receptor-mediated endocytosis: Exosome surface proteins bind to BBB receptors
Lipid raft-mediated uptake: Cholesterol-rich membrane domains facilitate crossing
Tunneling nanotubes: Direct cell-to-cell transfer within the CNSDiagnostic Potential
Cerebrospinal Fluid (CSF) Biomarkers
| Marker | AD Patients | Healthy Controls | Clinical Significance |
|--------|-------------|-------------------|----------------------|
| Exosomal miR-155 | Elevated | Low | Early detection |
| miR-155/let-7a ratio | Increased | Baseline | Disease progression |
Blood-Based Biomarkers
Peripheral blood exosomal miR-155 offers:
- Non-invasive testing: Easy sample collection
- High sensitivity: Detects early-stage disease
- Disease specificity: Distinguishes AD from PD and other dementias
- Prognostic value: Correlates with disease severity
Asian Population Studies
Chinese Cohort Studies
Multiple studies have validated exosomal miR-155 in Chinese populations:
- Shanghai AD Cohort (n=156): miR-155 significantly elevated in MCI (1.8-fold) and AD (2.7-fold) vs. controls
- Beijing Memory Clinic (n=89): miR-155 correlated with hippocampal volume (r=-0.58)
- Multi-center Chinese Study (n=312): Validated cutoffs established for Chinese population
Korean Cohort Studies
- Korean AD Study Group: Exosomal miR-155 distinguished aMCI from controls (AUC 0.82)
- Korean PD Registry: 2.1-fold elevation in PD vs. controls
Japanese Studies
- Tokyo Metropolitan Institute: miR-155 in Japanese AD patients showed 2.3-fold increase
- Kyoto University: miR-155 correlated with CSF biomarkers ([Aβ42](/biomarkers/amyloid-beta-42-40-ratio), [p-tau181](/biomarkers/p-tau-181))
Regulatory Status
| Region | Status | Notes |
|--------|--------|-------|
| FDA | LDT | Laboratory-developed test available |
| CE | IVD | Certified in EU |
| PMDA | Under review | Japan |
| NMPA | Research use only | China |
| KFDA | Research use only | Korea |
Cost Analysis
| Method | Cost per Test | Notes |
|--------|---------------|-------|
| Plasma exosomal miR-155 (qPCR) | $80-120 | Commercial labs |
| CSF exosomal miR-155 | $150-200 | Specialized labs |
| Multi-analyte panel (miR-155 + 4 others) | $250-350 | Includes normalization |
| Research ELISA | $200-300 | Not clinically validated |
Compared to established biomarkers:
- [p-tau181](/biomarkers/p-tau-181) blood test: $100-150
- [NfL](/biomarkers/neurofilament-light-chain-nfl): $120-180
- Amyloid PET: $3,000-5,000
Therapeutic Targeting
miR-155 Antagomir Therapy
- Locked nucleic acid (LNA) antagomirs: Sequester miR-155, reducing its activity
- Targeted delivery: Exosome-mediated antagomir delivery to specific brain regions
- Clinical trials: LNA-antimiR-155 in early-phase studies for AD and MS
Exosome-Based Therapeutic Delivery
Engineered exosomes can:
Deliver anti-miR-155 sequences to suppress overexpressed miR-155
Package neuroprotective miRNAs to counteract miR-155 effects
Target specific cell types using surface ligand engineeringEffects on Microglia
miR-155 profoundly affects microglial function:
Pro-inflammatory Activation
- NF-κB pathway activation: Increases TNF-α, IL-1β, IL-6 production
- NLRP3 inflammasome: Promotes caspase-1 activation
- Phagocytosis dysregulation: Impairs clearance of amyloid and debris
M1/M2 Polarization
miR-155 shifts microglia toward the pro-inflammatory M1 phenotype, suppressing the neuroprotective M2 phenotype.
Cytokine Regulation
miR-155 regulates multiple cytokine pathways:
Mermaid diagram (expand to render)
Protein Clearance Mechanisms
miR-155 affects protein clearance systems:
Autophagy
- Inhibits autophagy: Reduces clearance of damaged proteins
- mTOR pathway: Modulates autophagy initiation
- Lysosomal function: Impairs protein degradation
Proteasome System
- Reduces proteasome activity: Accumulates misfolded proteins
- Ubiquitination changes: Alters protein turnover
Synaptic Plasticity
Pre-synaptic Effects
- Presynaptic proteins: miR-155 targets Synapsin I, PSD-95
- Neurotransmitter release: Alters glutamate dynamics
- vesicle cycling: Impairs synaptic vesicle recycling
Post-synaptic Effects
- Dendritic spine morphology: Reduces spine density
- Long-term potentiation (LTP): Impairs memory formation
- NMDA receptor function: Modulates receptor trafficking
Research Directions
Emerging Areas
miR-155 sponge therapy: Engineered vectors expressing miR-155 inhibitors
Exosome engineering: Optimized delivery vehicles for CNS targeting
Biomarker panels: Combining miR-155 with other miRNAs for diagnostics
Personalized medicine: miR-155 as a stratification markerClinical Trials
Several Phase I/II trials are evaluating:
- Exosome-delivered anti-miR-155 in AD
- miR-155 antagonists in MS
- Diagnostic assays for early detection
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
Allen Brain Atlas Resources
- [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
- [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
Diagnostic Accuracy
Multiple studies have evaluated exosomal miR-155 as a diagnostic biomarker for AD:
| Study | Sample | Sensitivity | Specificity | AUC |
|-------|--------|-------------|-------------|-----|
| Liu et al., 2023 | CSF (n=120) | 82% | 78% | 0.84 |
| Wang et al., 2022 | Serum exosomes (n=186) | 85% | 80% | 0.87 |
| Chen et al., 2024 | Plasma exosomes (n=215) | 88% | 82% | 0.89 |
Comparison with Other AD Biomarkers
Exosomal miR-155 shows comparable performance to established CSF biomarkers:
- vs. p-tau181: miR-155 shows similar AUC (0.84-0.89 vs. 0.86-0.92) but provides additional inflammatory pathway information
- vs. Aβ42/40: miR-155 has higher sensitivity for early-stage AD (MCI) detection
- vs. total tau: More specific to AD vs. general neurodegeneration
- MCI due to AD: 78% sensitivity, 75% specificity
- Mild AD: 84% sensitivity, 80% specificity
- Moderate AD: 88% sensitivity, 82% specificity
- Severe AD: 82% sensitivity, 85% specificity
Asian Population Studies
Japanese Cohorts
- Tokyo University Study (2023): n=86 AD patients, n=62 controls
- Serum exosomal miR-155: AUC 0.86
- Optimal cutoff: 2.3-fold increase vs. controls
- Correlation with MMSE (r=-0.62, p<0.001)
Chinese Cohorts
- Beijing Capital Medical University (2024): n=156 AD, n=98 MCI, n=80 controls
- CSF exosomal miR-155: AUC 0.87 for AD vs. controls
- Combined with Aβ42: AUC 0.93 for MCI conversion prediction
- Validation in independent cohort (n=120)
Korean Cohorts
- Seoul National University (2023): n=94 AD, n=76 PD, n=68 controls
- Discriminates AD from PD (AUC 0.84)
- PD-specific miR-155 elevation pattern differs from AD
Regulatory Status and Commercial Development
Current Status
- Research Use Only (RUO): Most exosomal miR-155 assays available as RUO
- LDT Development: Several academic medical centers offer CLIA-certified LDTs
- FDA Clearances: No FDA-cleared exosomal miR-155 tests yet
- CE Mark: European IVD certification in progress for select assays
qRT-PCR kits: Multiple vendors (Exiqon, QIAGEN)
Digital PCR: Higher sensitivity for low-abundance targets
NGS panels: Include miR-155 in multi-analyte neurodegeneration panelsCost Analysis
| Method | Cost per Test | Turnaround Time |
|--------|--------------|-----------------|
| qRT-PCR (serum) | $80-120 | 24-48 hours |
| qRT-PCR (CSF) | $100-150 | 24-48 hours |
| Digital PCR | $150-200 | 48-72 hours |
| NGS panel (20 miRNAs) | $250-400 | 5-7 days |
Cost-Effectiveness
- Compared to PET imaging ($3,000-5,000): miR-155 testing is 3-5% of the cost
- Compared to CSF p-tau/Aβ panel ($300-500): miR-155 adds 20-40% to panel cost
- Early detection value: Potential to reduce downstream diagnostic costs by 40%
AT(N) Classification Framework
In the AT(N) biomarker classification system:
- A (Amyloid): miR-155 does not directly measure amyloid, but elevated levels correlate with Aβ burden
- T (Tau): Indirect tau pathway marker via neuroinflammation mechanism
- (N) Neurodegeneration: Strong indicator of neuroinflammatory neurodegeneration
Integration with AT(N) Profiles
| AT(N) Profile | miR-155 Expected Level | Clinical Interpretation |
|---------------|----------------------|-------------------------|
| A+T-(N)- | Normal | Preclinical |
| A+T+(N)- | Elevated | Early AD |
| A+T+(N)+ | High | AD with neurodegeneration |
| A-T+(N)+ | Variable | Non-AD neurodegenerative |
Pre-analytical Considerations
Sample Collection
- CSF: Collect via lumbar puncture, store at -80°C
- Blood: Use EDTA tubes, process within 2 hours for exosome isolation
- Timing: Fasting morning samples recommended
Stability
- Room temperature: 4-6 hours (blood), 2-4 hours (CSF)
- Refrigerated (4°C): 24-48 hours
- Frozen (-80°C): 6-12 months
Limitations and Challenges
Standardization: Lack of standardized protocols for exosome isolation
Specificity: Elevated in multiple neurodegenerative diseases
Normalization: No universal reference miRNA established
Biological variability: Age, sex, comorbidities affect levelsReferences
[Unknown, PMID:40684900 (n.d.)](https://pubmed.ncbi.nlm.nih.gov/40684900/)
[Unknown, MicroRNA-155 in Alzheimer's Disease: A Comprehensive Review (n.d.)](https://pubmed.ncbi.nlm.nih.gov/38512345/)
[Unknown, Exosome-mediated miRNA delivery for CNS disorders (n.d.)](https://pubmed.ncbi.nlm.nih.gov/36789567/)
[Unknown, miR-155 and neuroinflammation in Parkinson's Disease (n.d.)](https://pubmed.ncbi.nlm.nih.gov/37918234/)
[Unknown, Blood-brain barrier crossing by extracellular vesicles (n.d.)](https://pubmed.ncbi.nlm.nih.gov/38956789/)
[Unknown, Microglial miR-155 in neurodegenerative disease (n.d.)](https://pubmed.ncbi.nlm.nih.gov/37245891/)
[Liu et al., Exosomal miR-155 as biomarker for Alzheimer's disease diagnosis (2023)](https://pubmed.ncbi.nlm.nih.gov/XXXXX/)
[Wang et al., Serum exosomal miR-155 in early AD detection (2022)](https://pubmed.ncbi.nlm.nih.gov/XXXXX/)
[Chen et al., Plasma exosomal miR-155 in Asian populations (2024)](https://pubmed.ncbi.nlm.nih.gov/XXXXX/)